Literature DB >> 698033

Mexiletine in normal volunteers.

N P Campbell, J G Kelly, A A Adgey, R G Shanks.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 698033      PMCID: PMC1429474          DOI: 10.1111/j.1365-2125.1978.tb00868.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  4 in total

1.  Measurement of plasma mexiletine concentrations.

Authors:  J G Kelly
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Absorption, distribution and elimination of mexiletine.

Authors:  L F Prescott; A Pottage; J A Clements
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  The development of mexiletine in the management of ventricular dysrhythmias.

Authors:  N P Campbell; N C Chaturvedi; R G Shanks; J G Kelly; J E Strong; A A Adgey
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

4.  The clinical pharmacology of mexiletine.

Authors:  N P Campbell; J G Kelly; A A Adgey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

  4 in total
  8 in total

Review 1.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

2.  Enhanced metabolism of mexiletine after phenytoin administration.

Authors:  E J Begg; P M Chinwah; C Webb; R O Day; D N Wade
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

3.  Absorption of mexiletine after treatment with gastric antacids.

Authors:  P Herzog; K H Holtermüller; W Kasper; T Meinertz; D Trenk; E Jähnchen
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

5.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

6.  Plasma mexiletine concentrations following combined oral and intramuscular administration.

Authors:  I D Bradbrook; P Feldschreiber; P J Morrison; H J Rogers; R G Spector
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

7.  Stereoselective disposition of mexiletine in man.

Authors:  O Grech-Belanger; J Turgeon; M Gilbert
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

8.  Pharmacokinetics of mexiletine in renal insufficiency.

Authors:  D El Allaf; L Henrard; L Crochelet; D Delapierre; J Carlier; A Dresse
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.